The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may help people cut down on drinking.

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Sales of weight loss drug Wegovy more than doubled in the final three months of 2024, as manufacturer Novo Nordisk predicted growth will slow this year. The Danish pharmaceutical company has ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat. Combined, they brought in $24.9 billion for the year. That's compared ...